<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lupus nephritis: Diagnosis and classification</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lupus nephritis: Diagnosis and classification</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Lupus nephritis: Diagnosis and classification</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew S Bomback, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gerald B Appel, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Pisetsky, MD, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 09, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2187794401"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Kidney involvement is common in systemic lupus erythematosus (SLE). An abnormal urinalysis with or without an elevated plasma creatinine concentration is present in a large proportion of patients at the time of diagnosis of lupus nephritis (LN).</p><p>An overview of the epidemiology, pathogenesis, diagnosis, and classification of LN will be presented here. The approach to therapy in the different types of LN is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3093.html" rel="external">"Lupus nephritis: Therapy of lupus membranous nephropathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3066.html" rel="external">"Kidney transplantation in adults: Issues related to lupus nephritis"</a>.)</p><p></p><p class="headingAnchor" id="H216949728"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Most patients with systemic lupus erythematosus (SLE) will have clinical evidence of kidney disease, usually an abnormal urinalysis, at some point in the course of their disease [<a href="#rid1">1-4</a>]. Lupus nephritis (LN) typically develops early in the disease course [<a href="#rid5">5</a>]. Clinically evident kidney disease eventually occurs in up to one-half of patients with SLE, and up to 10 percent of patients with LN will develop end-stage kidney disease (ESKD) [<a href="#rid1">1,6-18</a>]. In one cohort of 1827 patients with newly diagnosed SLE, LN occurred in 700 (38 percent) patients followed for a mean of 4.6 years [<a href="#rid19">19</a>]. The overall 10-year incidence of ESKD was 4 percent and, in patients with LN, 10 percent. In this cohort, LN was also associated with a threefold increased risk of death. Study-to-study variations in prevalence estimates of LN may be due in part to racial differences in disease prevalence and/or risk of nephropathy, as well as varying definitions and/or disease ascertainment [<a href="#rid14">14,18,20,21</a>].</p><p>There is a higher incidence of LN among patients with SLE in the United States as compared with Europe, which may in part reflect racial and ethnic differences [<a href="#rid12">12,15-17</a>]. The incidence of LN is higher in Black patients with SLE (34 to 51 percent), Hispanic patients (31 to 43 percent), and Asian patients (33 to 55 percent) than it is in White patients (14 to 23 percent) [<a href="#rid5">5-9,21</a>]. Black patients and Hispanic patients also tend to present with more severe underlying histopathology, higher serum creatinine concentrations, and more proteinuria than White patients [<a href="#rid5">5,22</a>]. In addition, Black patients, Hispanic patients, and those living in poverty have a worse prognosis than White patients and those with a higher socioeconomic status. However, the higher frequency of LN in Black populations persists even after correction for socioeconomic factors [<a href="#rid21">21-23</a>].</p><p>The time course for the development of LN varies with sex, age, and ethnicity. In a retrospective study in the United States, males, younger patients (eg, less than 33 years of age at diagnosis), and patients who are not White were at enhanced risk of developing nephritis earlier in the course of the disease [<a href="#rid13">13</a>]. A number of patient characteristics place patients with LN at greater risk for progressive kidney disease including African or Hispanic ancestry, male sex, pediatric onset, frequent relapses or incomplete remission, and proteinuria &gt;4 g/day at diagnosis [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H2713063806"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Although lupus nephritis (LN) is considered to be a classic form of immune complex glomerulonephritis, the pathogenesis of LN is complicated. The pathogenesis may involve the expression of genes, both in the peripheral blood as well as in the kidneys, leading to neutrophil activation and increased expression of interferon and upregulation of myeloid cell and proinflammatory transcriptomes [<a href="#rid1">1,25-27</a>]. Neutrophils and dying neutrophils may release neutrophil extracellular traps (NETs) composed of chromatin, histones, and immunostimulatory proteins that become a source of nuclear antigens allowing antigen-specific autoantibody production [<a href="#rid28">28</a>]. NET degradation has been found to be decreased in patients with systemic lupus erythematosus (SLE) and especially in those with LN [<a href="#rid29">29</a>]. Complement activation in LN may damage the kidney through endothelial damage and enhancement of kidney inflammation [<a href="#rid30">30</a>].</p><p>The pattern of glomerular injury seen in SLE (and in other immune complex-mediated glomerular diseases) is generally related to the site of formation of the immune deposits, which are primarily due to anti-double-stranded DNA (anti-dsDNA or anti-DNA) antibodies. These antibodies bind DNA in various forms, such as DNA in the form of nucleosomes, which consist of double-stranded DNA (dsDNA) wound around a core histone octamer [<a href="#rid10">10</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-dsDNA immune complex formation</strong> – These immune complexes are primarily composed of DNA and anti-dsDNA. However, immune complexes may also have as their components chromatin, C1q, laminin, Sm, La (SS-B), Ro (SS-A), ubiquitin, ribosomes, and glomerular elements including the parts of the glomerular basement membrane (GBM) and mesangium [<a href="#rid31">31-38</a>]. The immune deposits in LN can occur in the mesangium, subendothelial, and/or subepithelial compartments of the glomerulus.</p><p></p><p class="bulletIndent1">The site of immune complex formation is related to the characteristics of both the antigen and antibody:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mesangium and subendothelial space</strong> – Large, intact immune complexes or anionic antigens (which cannot cross the anionic charge barrier in the glomerular capillary wall) are deposited in the mesangium and subendothelial space [<a href="#rid31">31,32</a>]. These deposits are proximal to the GBM and are therefore in communication with the vascular space. As a result, activation of complement (typically via the classical pathway) with the generation of the chemoattractants, C3a and C5a, results in the influx of neutrophils and mononuclear cells. These changes are manifested histologically by a mesangial, focal, or diffuse proliferative glomerulonephritis and clinically by an active urine sediment (red cells, white cells, and cellular and granular casts), proteinuria, and, often, an acute decline in kidney function.</p><p></p><p class="bulletIndent2">The degree and nature of immune deposition as well as the response to the deposits determine whether the patient develops mild disease limited to the mesangium or a more severe focal or diffuse proliferative glomerulonephritis. (See  <a class="medical medical_review" href="/z/d/html/3068.html" rel="external">"Mechanisms of immune injury of the glomerulus"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subepithelial space</strong> – Experimental studies suggest that there are two primary mechanisms by which subepithelial deposits may form: a cationic antigen that can cross the GBM and fix in a subepithelial location with subsequent antibody complexing or an autoantibody may be directed against an endogenous epithelial cell antigen [<a href="#rid39">39</a>]. Although deposits in the subepithelial space can also activate complement, there is no influx of inflammatory cells, since the chemoattractants are separated from the circulation by the GBM. Thus, injury is limited to the glomerular epithelial cells, and the primary clinical manifestation is proteinuria, which is often in the nephrotic range. Histologically, these patients most commonly have membranous nephropathy.</p><p></p><p class="bulletIndent1">Immune complex deposition can activate other arms of the inflammatory response:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Upregulation and activation of adhesion molecules on endothelium can result in the recruitment of proinflammatory leukocytes and the initiation of autoimmune injury [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/3983.html" rel="external">"Leukocyte-endothelial adhesion in the pathogenesis of inflammation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Activated mesangial cells, infiltrating macrophages, and B and T cells produce inflammatory cytokines, including tumor necrosis factor (TNF)-alpha, interleukin (IL) 6, tumor growth factor-beta, interferon-gamma, chemokines, and platelet-derived growth factor. All of these inflammatory mediators have the potential to extend kidney injury [<a href="#rid41">41-44</a>]. Activated platelets may also contribute to mesangial cell proliferation [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1">Although kidney disease is primarily due to anti-dsDNA complexes, some data suggest that autoantibodies against C1q, a complement component, may correlate with LN [<a href="#rid46">46-48</a>]. These antibodies may promote disease by binding to C1q that has been fixed on immune complexes on the GBM [<a href="#rid49">49</a>]. The binding of anti-C1q antibodies to C1q activates complement, resulting in an influx of inflammatory cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other mechanisms</strong> – The induction of nephritis by anti-dsDNA may not require immune complex formation. Anti-dsDNA antibodies appear to bind to human mesangial cells in vitro and induce production of proinflammatory substances [<a href="#rid50">50,51</a>]. In an in vitro system, for example, anti-dsDNA isolated during active LN induced mesangial cell production of IL-1 (and other proinflammatory substances), which in turn increased synthesis of hyaluronan (an extracellular matrix component that accumulates during tissue injury and recruits lymphocytes) [<a href="#rid51">51</a>]. The plasma cells that secrete these autoantibodies have been located not just in the spleen and bone marrow but also in the tubulointerstitium of the cortex and outer medulla of the kidney [<a href="#rid52">52</a>]. Thus, the kidney may be a major site of autoreactive plasma cells in LN.</p><p></p><p class="bulletIndent1">Neutrophils and NETs may add to antigen-specific autoantibody production facilitating inflammation, endothelial damage, and local interferon alpha production in the kidney [<a href="#rid1">1,28,29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – A variety of genes and genetic factors reportedly predispose patients to the development of SLE and influence the clinical picture of kidney disease in SLE [<a href="#rid53">53</a>]. A meta-analysis of studies evaluating the relationship between polymorphisms of <em>HLA-DRB1</em> alleles and SLE found that some genotypes (<em>HLA-DR4</em> and <em>-DR11</em>) conferred protection from LN while others were associated with an increased risk of LN (<em>HLA-DR3</em> and <em>-DR15</em>) [<a href="#rid54">54</a>]. Another meta-analysis found a stronger association between the genes for <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.genenames.org%2Fdata%2Fgene-symbol-report%2F&amp;token=F%2F33Yq3Lpx4WKgz%2BcwHiE8qYcjNNXE5X9jWjCIF6FqRshqNyUkB0Di2UvEHQ4%2FlXYudngrxreRAYbS3LRIYXrA%3D%3D&amp;TOPIC_ID=3056" target="_blank">platelet derived growth factor receptor alpha</a> (<em>PDGFRA</em>) and solute carrier family 5 member 11 (<em>SLC5A11</em>)<em> </em>and LN compared with human leukocyte antigen (HLA) loci [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/z/d/html/4669.html" rel="external">"Epidemiology and pathogenesis of systemic lupus erythematosus", section on 'Genetic factors'</a>.)</p><p></p><p class="bulletIndent1">The increased frequency and severity of LN among African Americans has led to the examination of genetic factors that might predispose them to LN [<a href="#rid56">56-61</a>]. Polymorphisms in the immunoglobulin receptor alleles Fc-gamma-RIIa-H131, present on macrophages, have been associated with susceptibility to LN in some studies [<a href="#rid56">56,60</a>], although conflicting data exist [<a href="#rid57">57</a>]. Other studies have noted an association between polymorphisms in the Fc-gamma-RIIIa-F158 receptor allele and Fc-gamma-RIIIb and LN [<a href="#rid58">58,59</a>].</p><p></p><p class="bulletIndent1">These polymorphisms result in alterations of the binding avidity of the receptors to their specific immunoglobulin G (IgG) subclasses [<a href="#rid58">58</a>]. It is hypothesized that this change permits the inappropriate deposition of circulating immune complexes in the kidney (and elsewhere) due to inadequate clearance by hepatic and splenic macrophages [<a href="#rid56">56</a>]. These differences may contribute to a worse prognosis in LN. As an example, African Americans have higher frequencies of certain Fc-gamma-RIIa-R131 alleles associated with phagocytosis of IgG2 immune complexes [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1">Two <em>APOL1</em> gene variants (APO L1 G1 and G2) that are found almost exclusively in African Americans have been associated with glomerulosclerosis and disease progression in a number of disorders including LN [<a href="#rid62">62,63</a>]. (See  <a class="medical medical_review" href="/z/d/html/3824.html" rel="external">"Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis"</a> and  <a class="medical medical_review" href="/z/d/html/14026.html" rel="external">"HIV-associated nephropathy (HIVAN)"</a>.)</p><p></p><p class="headingAnchor" id="H1715545243"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Kidney disease is typically detected in most patients with systemic lupus erythematosus (SLE) by an abnormal urinalysis with or without an elevated plasma creatinine concentration. The most frequently observed abnormality in patients with lupus nephritis (LN) is proteinuria [<a href="#rid1">1,4,5,64</a>]. Other common clinical manifestations include microscopic hematuria with or without red cell casts, kidney function impairment, nephrotic-range proteinuria or nephrotic syndrome, and hypertension [<a href="#rid1">1</a>]. As a result, all patients with SLE should be routinely monitored for kidney disease. (See <a class="local">'When to suspect LN'</a> below.)</p><p>Most kidney abnormalities emerge soon after the diagnosis of SLE is made (commonly, within the first 6 to 36 months) [<a href="#rid1">1,13,65</a>]. In some cases, manifestations of LN are the presenting features of SLE [<a href="#rid66">66</a>]. An elevated plasma creatinine concentration eventually develops in approximately 30 percent of all patients with SLE.</p><p>Rarely, patients may have silent LN, in which significant abnormalities are observed on kidney biopsy without any clinical signs of kidney involvement. Studies in which a kidney biopsy is performed in patients without any clinical evidence of kidney disease have found mesangial, focal, or diffuse proliferative glomerulonephritis in some patients [<a href="#rid67">67-70</a>]. As an example, a cohort study evaluated the kidney pathology of 195 patients with SLE, 86 of whom had no clinical kidney involvement; among those without clinical kidney involvement, 13 (15 percent) had either class III or IV LN, and 9 (10 percent) had class V (membranous) disease [<a href="#rid70">70</a>].</p><p>The kidney disease in patients with silent LN often remains clinically silent and is associated with a benign kidney outcome [<a href="#rid67">67,70</a>]. Some patients, however, progress to overt nephritis [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H4123094508"><span class="h1">EVALUATION AND DIAGNOSIS</span></p><p class="headingAnchor" id="H1153095444"><span class="h2">When to suspect LN</span><span class="headingEndMark"> — </span>The presence of lupus nephritis (LN) should be suspected in patients with known systemic lupus erythematosus (SLE) who develop an active urinary sediment with persistent hematuria (five or more red blood cells, most of which are dysmorphic, per high-power field) and/or cellular casts, proteinuria, and/or an elevated serum creatinine (or decrease in estimated glomerular filtration rate [eGFR]) [<a href="#rid2">2,3</a>]. Elevated anti-double-stranded-DNA (anti-dsDNA) titers and low complement (C3 and C4) levels often indicate active SLE, particularly LN, although the utility of serological assessment differs among patients.</p><p>All patients with known SLE should undergo laboratory testing to assess for kidney involvement at regular intervals. The frequency with which monitoring laboratory tests are performed is tailored to each patient and is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Monitoring response to therapy'</a>.)</p><p>There are some patients for whom signs and symptoms of LN are the predominant presenting symptoms resulting in the diagnosis of SLE. The approach to diagnosing SLE in such patients is reviewed in a separate topic. (See  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H3195177308"><span class="h2">Establishing the diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of LN is ideally confirmed by a kidney biopsy [<a href="#rid2">2,3,71</a>]. A kidney biopsy is important to define the nature of kidney involvement, exclude other causes of kidney injury, and determine the histopathologic subtype of LN. Biopsies are also important to assess disease activity and chronicity. (See <a class="local">'Histopathologic classification of LN'</a> below.)</p><p class="headingAnchor" id="H1534230209"><span class="h3">Role of kidney biopsy</span><span class="headingEndMark"> — </span>A kidney biopsy should be performed in most patients with SLE who have clinical or laboratory evidence of kidney involvement (eg, abnormal proteinuria, active urine sediment, elevated serum creatinine and/or decreased glomerular filtration rate [GFR]) to establish the correct diagnosis and determine the histologic subtype of LN. However, as with any other invasive procedure, an individualized risk-benefit assessment is required prior to performing the procedure. (See  <a class="medical medical_review" href="/z/d/html/3067.html" rel="external">"The kidney biopsy", section on 'Appropriate use of kidney biopsy'</a>.)</p><p>We generally perform a kidney biopsy in patients who have one or more of the following clinical manifestations:</p><p class="bulletIndent1"><span class="glyph">●</span>Urine protein excretion greater than 500 mg/day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An active urinary sediment with persistent hematuria (five or more red blood cells per high-power field, most of which are dysmorphic) and/or cellular casts. The urine may be contaminated with vaginal blood in menstruating women or with bladder red cells with urinary tract infections. Red cells from these sources are not dysmorphic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A rising serum creatinine that is not clearly attributable to another mechanism.</p><p></p><p>Our approach is consistent with the indications for kidney biopsy included in the joint European Alliance of Associations for Rheumatology (formerly known as European League Against Rheumatism)/European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) guidelines [<a href="#rid72">72</a>].</p><p>Determining the nature and class of LN is important for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment is guided by the histologic subtype (ie, the International Society of Nephrology/Renal Pathology Society [ISN/RPS] class, the degree of activity and chronicity) and by complicating lesions such as interstitial nephritis and thrombotic microangiopathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biopsy may also identify entities other than LN. Some patients with SLE and nephrotic-range proteinuria will have a lupus podocytopathy without major immune complex deposition but with effaced foot processes as seen in minimal change disease. Others with kidney disease may have a thrombotic microangiopathy or predominant tubulointerstitial involvement rather than major glomerular involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical presentation may not accurately reflect the severity of the histologic findings. As an example, infrequently, proliferative lupus may be present even if the patient has minimal proteinuria and normal serum creatinine.</p><p></p><p>We generally do not perform a kidney biopsy in patients with proteinuria that is less than 500 mg/day and a bland urine sediment. Such patients are unlikely to have focal or diffuse LN or lupus membranous nephropathy. They may have minimal mesangial or mesangial proliferative disease, neither of which requires immunosuppressive therapy. Such patients should still be monitored for evidence of progressive disease such as increasing proteinuria, emergence of an active sediment, and/or an increase in serum creatinine. These manifestations suggest transformation to a more severe lesion and warrant kidney biopsy. Data supporting close monitoring of patients with low-grade proteinuria are provided by a study of 151 patients with SLE and proteinuria ≥0.2 and &lt;0.5 g/g, which found that half progressed to a urine protein-to-creatinine ratio of ≥0.5 g/g within one to two years [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Laboratory evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Monitoring response to therapy'</a>.)</p><p class="headingAnchor" id="H2709827351"><span class="h4">Characteristic histopathologic findings</span><span class="headingEndMark"> — </span>The histopathology of LN can be quite varied, and at times, LN may be confused with other immune complex-mediated glomerulonephritides. However, some histopathologic features are highly characteristic of LN. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Glomerular deposits that stain dominantly for IgG and contain codeposits of immunoglobulin A (IgA), immunoglobulin M (IgM), C3, and C1q, the so-called "full house" immunofluorescence pattern. Less commonly, the "full house" immunofluorescence pattern may also be seen in patients with endocarditis [<a href="#rid74">74</a>], HIV [<a href="#rid75">75</a>], hepatitis C [<a href="#rid76">76</a>], a portosystemic shunt [<a href="#rid77">77</a>], and poststreptococcal glomerulonephritis. In addition, intense staining for C1q has also been shown to have a similar sensitivity and specificity for LN as the "full house" staining pattern [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glomerular deposits simultaneously seen in the mesangial, subendothelial, and subepithelial locations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extraglomerular immune-type deposits within tubular basement membranes, the interstitium, and blood vessels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tubuloreticular inclusions in the glomerular endothelial cells  (<a class="graphic graphic_picture graphicRef79072" href="/z/d/graphic/79072.html" rel="external">picture 1</a>). These inclusions are composed of ribonucleoprotein and membrane, and their synthesis is stimulated by alpha-interferon [<a href="#rid79">79</a>]. The only other circumstances in which these structures are prominent are in HIV nephropathy (associated with chronically high levels of circulating alpha-interferon) and treatment with alpha-interferon. However, patients with HIV nephropathy typically have collapsing focal segmental glomerulosclerosis without evidence of immune complexes rather than a proliferative glomerulonephritis with immune complex deposition. (See  <a class="medical medical_review" href="/z/d/html/14026.html" rel="external">"HIV-associated nephropathy (HIVAN)"</a>.)</p><p></p><p class="headingAnchor" id="H2309432319"><span class="h4">Timing of initial biopsy</span><span class="headingEndMark"> — </span>Ideally, a kidney biopsy is performed promptly (ie, within days to weeks) in patients who have an appropriate indication. Prompt diagnosis after the onset of LN and subsequent initiation of appropriate therapy are associated with improved outcomes, regardless of the histologic class [<a href="#rid80">80-82</a>]. A rapidly rising serum creatinine and/or the development of new nephrotic-range proteinuria are indications for urgent kidney biopsy so that an accurate diagnosis can be established, and appropriate treatment can be initiated as soon as possible.</p><p>The potential magnitude of the increase in risk with delayed kidney biopsy was illustrated in a study of 91 patients with LN who were followed for a median of six years. Patients who had clinically recognized kidney disease for six or more months prior to biopsy had a much higher rate of end-stage kidney disease (ESKD; 47 versus 14 per 1000 patient-years for those who had an earlier biopsy; hazard ratio 9.3, 95% CI 1.8-47.0) [<a href="#rid80">80</a>]. Similar findings were noted in another report in which the relative risk for subsequent kidney function impairment was 4.9 in patients with a delay between the time of detection of kidney disease and first kidney biopsy [<a href="#rid81">81</a>].</p><p class="headingAnchor" id="H1438176153"><span class="h4">When to repeat the biopsy</span><span class="headingEndMark"> — </span>The indications for a repeat biopsy include the emergence of an active sediment in someone with previously quiescent disease, a new elevation in serum creatinine, and/or worsening of proteinuria despite treatment [<a href="#rid83">83-86</a>]. In a report from a single institution, transformation from one histologic pattern to another (most frequently from focal to diffuse LN or from diffuse to advanced sclerosing LN) was noted in more than one-half of patients who underwent repeat kidney biopsy [<a href="#rid84">84</a>].</p><p>The utility of repeat biopsy depends in part upon the histologic diagnosis obtained on the initial biopsy. Among patients with lupus membranous nephropathy, a repeat biopsy is warranted for those who develop an active sediment or a rising serum creatinine since these findings suggest transformation to a class III or IV lesion, which usually requires different treatment. In a retrospective study of 29 patients with lupus membranous nephropathy, the probability of a transition from membranous to class III or IV nephritis at 10 years was 35 percent [<a href="#rid83">83</a>]. By contrast, recurrence of proteinuria generally is <strong>not</strong> an indication for repeat biopsy in lupus membranous nephropathy, since relapse of isolated proteinuria is common, especially after immunosuppressive therapy with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [<a href="#rid87">87</a>]. (See  <a class="medical medical_review" href="/z/d/html/3093.html" rel="external">"Lupus nephritis: Therapy of lupus membranous nephropathy"</a>.)</p><p>The value of a repeat biopsy has been debated. Some feel a repeat biopsy may not be necessary in patients with successfully treated diffuse LN who develop a recurrent active sediment that almost certainly represents recurrent diffuse disease. Kidney biopsy is unlikely to provide any additional data that would affect treatment in most such patients. Others feel that there may be a discordance between the clinical findings suggesting remission and persistent histologic activity in the repeat biopsy [<a href="#rid88">88-91</a>]. (See  <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis"</a>.)</p><p>Settings in which repeat kidney biopsy is helpful include:</p><p class="bulletIndent1"><span class="glyph">●</span>Increasing proteinuria. In one report, increasing proteinuria was the indication for repeat biopsy in 45 of 57 patients with LN who had at least two kidney biopsies [<a href="#rid86">86</a>]. Also, new or worsening nephrotic syndrome in patients with treated class III or IV LN may reflect a concurrent membranous lesion, which may require a different approach to therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An active urine sediment and a rapidly rising serum creatinine. This might reflect crescentic disease that may warrant more aggressive initial therapy, such as pulse glucocorticoids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Slowly rising serum creatinine or persistent proteinuria. The goal of repeat biopsy is to distinguish active LN from advanced sclerosing LN (class VI) alone, which would not be treated with immunosuppressive therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suspicion of possible kidney disease unrelated to LN (eg, drug-induced acute interstitial nephritis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Helping to guide the tapering or withdrawal of immunosuppressives in patients on long-term maintenance therapy who are in clinical remission. In a single-center study, 44 patients with LN underwent a repeat kidney biopsy and withdrawal of maintenance immunosuppression after they were in clinical remission for at least 12 months and on maintenance immunosuppression for at least 36 months [<a href="#rid92">92</a>]. Forty-four percent of the patients had persistent histologic activity on repeat kidney biopsy despite being in a clinical remission on maintenance therapy. After withdrawal of maintenance immunosuppression, LN flared in 35 percent of patients. Ninety-one percent of flares occurred in patients with active histopathology on repeat biopsy.</p><p></p><p>There is no consensus among the authors and editors of this topic on when to perform repeat kidney biopsy in patients with slowly progressive chronic kidney disease. Such patients may have nonimmunologic injury induced by nephron loss from previous inflammatory disease, with subsequent intraglomerular hypertension and hyperfiltration. Clinical manifestations in these patients may include a gradual increase in protein excretion (non-nephrotic), a bland urine sediment without hematuria (although residual hematuria can occasionally be seen), and a gradual increase in serum creatinine. In a study of 45 patients who had a repeat kidney biopsy for the evaluation of increasing proteinuria, the most common finding was a decrease in active lesions and an increase in chronic changes [<a href="#rid86">86</a>]. Treatment in these patients generally does not involve immunosuppressive therapy, but continued monitoring for signs of active kidney disease is recommended. However, possible indications for repeat kidney biopsy include the presence of antiphospholipid antibodies (which can cause kidney disease with a bland urine sediment), active extrarenal lupus, and markedly elevated anti-dsDNA antibody titers with or without hypocomplementemia. (See  <a class="medical medical_review" href="/z/d/html/3073.html" rel="external">"Antiphospholipid syndrome and the kidney", section on 'Kidney disease in APS associated with systemic lupus erythematosus'</a>.)</p><p class="headingAnchor" id="H2358227561"><span class="h3">Histopathologic classification of LN</span><span class="headingEndMark"> — </span>Based upon clinicopathologic correlations derived from kidney biopsy, a lupus nephritis (LN) classification system was developed by a group of kidney pathologists, nephrologists, and rheumatologists in 2004 (the ISN/RPS classification) and revised in 2018 [<a href="#rid93">93-96</a>]. The revised ISN/RPS classification system divides glomerular disorders associated with SLE into six different patterns (or classes) based upon kidney biopsy histopathology [<a href="#rid93">93,94,96</a>]. LN activity and chronicity indices have also been proposed to provide more granularity to the diagnosis of active and chronic lesions [<a href="#rid96">96</a>]. (See <a class="local">'Activity and chronicity'</a> below.)</p><p>Although the different classes tend to have distinct histologic, clinical, and prognostic characteristics, there is substantial overlap due in part to variations in sampling. In addition, a significant percentage of patients evolve from one class of LN to another, sometimes after therapy and sometimes spontaneously [<a href="#rid84">84,93,97-100</a>]. The evolution from one class of nephritis to another is not surprising, since the different histologic types represent nonspecific responses to immune complex deposition.</p><p>Although various serologic and urine markers have been examined as potential noninvasive determinants of histologic class [<a href="#rid101">101-104</a>], no serum or urine marker of disease activity provides the degree of information that is gained by histopathology. Thus, classification of LN is determined by kidney biopsy [<a href="#rid96">96</a>].</p><p class="headingAnchor" id="H1151953968"><span class="h4">Minimal mesangial LN (class I)</span><span class="headingEndMark"> — </span>This class of lupus nephritis (LN) is rarely, if ever, diagnosed because these patients typically have a normal urinalysis, no or minimal proteinuria, and a normal serum creatinine. As a result, a biopsy is not usually performed. Patients with class I disease have only mesangial immune deposits that are identified by immunofluorescence alone or by both immunofluorescence and electron microscopy, but such patients do not have light microscopic abnormalities. Minimal mesangial LN (class I) represents the earliest and mildest form of glomerular involvement.</p><p class="headingAnchor" id="H3062275640"><span class="h4">Mesangial proliferative LN (class II)</span><span class="headingEndMark"> — </span>The histologic changes with class II disease are manifested clinically by microscopic hematuria and/or proteinuria. Hypertension is uncommon, and nephrotic syndrome and kidney function impairment are virtually never seen.</p><p>Light microscopy with class II disease reveals mesangial hypercellularity (of any degree) or mesangial matrix expansion  (<a class="graphic graphic_picture graphicRef80250" href="/z/d/graphic/80250.html" rel="external">picture 2</a>). A few isolated subepithelial or subendothelial deposits may be seen on immunofluorescence or electron microscopy. Visible subendothelial deposits on light microscopy or any global or segmental glomerular scars (which are thought to be the result of previous endocapillary hypercellularity, necrosis, or crescents) are inconsistent with the diagnosis of class II LN. Such findings would indicate either class III or IV disease. Extensive podocyte effacement with nephrotic syndrome can rarely be seen, resembling minimal change disease if there is an associated podocytopathy.</p><p>The kidney prognosis with mesangial proliferative LN is excellent, and no specific therapy is indicated unless the patient progresses to more advanced disease or has evidence of extensive podocyte effacement and nephrosis. (See <a class="local">'Lupus podocytopathy'</a> below.)</p><p class="headingAnchor" id="H721955151"><span class="h4">Focal LN (class III)</span><span class="headingEndMark"> — </span>Patients with class III lupus nephritis (LN) usually have hematuria and proteinuria, and some patients will also have hypertension, a decreased GFR, and/or nephrotic syndrome. Class III disease is defined histologically by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Less than 50 percent of glomeruli are affected by light microscopy. If more than 50 percent are involved, then the disease would be defined as diffuse LN (class IV). Although less than 50 percent of glomeruli are affected on light microscopy, immunofluorescence microscopy (for IgG and C3) reveals almost uniform involvement [<a href="#rid105">105</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Active or inactive endocapillary or extracapillary glomerulonephritis is almost always segmental (ie, involves less than 50 percent of the glomerular tuft) [<a href="#rid94">94</a>]. Electron microscopy usually reveals immune deposits in the subendothelial space of the glomerular capillary wall as well as the mesangium.</p><p></p><p>Determining prognosis in class III disease may be limited by the inability to accurately determine the percent of glomeruli involved. This latter feature relates to possible sampling error induced by the relatively small number of glomeruli that are obtained on a typical percutaneous kidney biopsy. (See  <a class="medical medical_review" href="/z/d/html/3067.html" rel="external">"The kidney biopsy"</a>.)</p><p>The treatment of focal LN is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis"</a>.)</p><p class="headingAnchor" id="H252019922"><span class="h4">Diffuse LN (class IV)</span><span class="headingEndMark"> — </span>Class IV LN is the most common histologic pattern seen on biopsy and most severe form of lupus nephritis (LN) [<a href="#rid106">106</a>]. Hematuria and proteinuria are present in virtually all patients with active class IV disease, and nephrotic syndrome, hypertension, and reduced GFR are all frequently seen. Affected patients typically have significant hypocomplementemia (especially C3) and elevated anti-dsDNA levels, especially during active disease [<a href="#rid107">107</a>].</p><p>Class IV LN is defined histologically by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>More than 50 percent of glomeruli are affected by light microscopy  (<a class="graphic graphic_picture graphicRef60218" href="/z/d/graphic/60218.html" rel="external">picture 3</a>). If less than 50 percent are involved, then the disease would be defined as focal LN (class III).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Affected glomeruli display endocapillary with or without extracapillary glomerulonephritis. Mesangial abnormalities may also be observed. Electron microscopy reveals subendothelial deposits, at least during the active phase  (<a class="graphic graphic_picture graphicRef79072" href="/z/d/graphic/79072.html" rel="external">picture 1</a>). The presence of diffuse wire loop deposits, but with little or no glomerular proliferation, is also considered class IV disease.</p><p></p><p>With active disease, hypercellular, necrotizing lesions, and crescent formation all may be present, affecting more than 50 percent of glomeruli on light microscopy [<a href="#rid105">105,106</a>]. The marked deposition of immunoglobulins (especially IgG) and complement (especially C3) in this setting  (<a class="graphic graphic_picture graphicRef70781" href="/z/d/graphic/70781.html" rel="external">picture 4</a>) results in thickening of the glomerular capillary wall  (<a class="graphic graphic_picture graphicRef79072" href="/z/d/graphic/79072.html" rel="external">picture 1</a>) and a pattern on light microscopy that is similar to that in membranoproliferative glomerulonephritis. These lesions are characterized by the marked influx of proinflammatory cells (monocytes, suppressor/cytotoxic T cells), sometimes resulting in cellular crescents [<a href="#rid108">108,109</a>].</p><p>The treatment of diffuse LN is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis"</a>.)</p><p class="headingAnchor" id="H3146535418"><span class="h4">Lupus membranous nephropathy (class V)</span><span class="headingEndMark"> — </span>Lupus membranous nephropathy is present in 10 to 20 percent of patients with LN [<a href="#rid97">97,110,111</a>]. Patients with class V LN typically present with signs of the nephrotic syndrome, similar to that in primary membranous nephropathy [<a href="#rid31">31,97,111</a>]. Microscopic hematuria and hypertension may also be seen at presentation, and the creatinine concentration is usually normal or only slightly elevated.</p><p>Class V disease is characterized by diffuse thickening of the glomerular capillary wall on light microscopy  (<a class="graphic graphic_picture graphicRef56549" href="/z/d/graphic/56549.html" rel="external">picture 5</a>) and by subepithelial immune deposits (either global or segmental involvement) on immunofluorescence or electron microscopy  (<a class="graphic graphic_picture graphicRef69348" href="/z/d/graphic/69348.html" rel="external">picture 6</a>) [<a href="#rid94">94,111,112</a>]. Mesangial involvement may also be seen.</p><p>Although sparse subendothelial deposits can be seen by immunofluorescence or electron microscopy with class V disease alone, the presence of such deposits as detected by light microscopy warrants a combined diagnosis of classes III and V disease or of classes IV and V disease. In this setting, the additional designation of class III or IV is based upon the distribution of the deposits.</p><p>Lupus membranous nephropathy may present with <strong>no other clinical or serologic manifestations of SLE</strong> (eg, complement levels may be normal, and anti-dsDNA antibodies may not be detectable) [<a href="#rid87">87,111,113-115</a>]. There are, however, several findings on electron and immunofluorescence microscopy that, if present, strongly suggest underlying lupus rather than primary membranous nephropathy. These issues and the treatment of lupus membranous nephropathy are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3093.html" rel="external">"Lupus nephritis: Therapy of lupus membranous nephropathy"</a>.)</p><p>The presence of significant hematuria and cellular casts with or without an elevated serum creatinine suggests concurrent proliferative disease, which is not uncommon and is associated with a much worse prognosis than class V alone. In a review of 79 patients with lupus membranous nephropathy, 36 had pure membranous lesions, 15 had endocapillary proliferation and/or necrosis in less than 50 percent of glomeruli, and 28 had endocapillary proliferation and/or necrosis in more than 50 percent of glomeruli [<a href="#rid116">116</a>].</p><p class="headingAnchor" id="H2411182677"><span class="h4">Advanced sclerosing LN (class VI)</span><span class="headingEndMark"> — </span>Patients with advanced sclerosing glomerulonephritis usually display slowly progressive kidney dysfunction in association with proteinuria and a relatively bland urine sediment. Class VI disease is characterized by global sclerosis of more than 90 percent of glomeruli. It represents healing of prior inflammatory injury, as well as the advanced stage of chronic class III, IV, or V lupus nephritis (LN). Active glomerulonephritis should not be observed. A retrospective study found that 4 percent of 169 kidney biopsies from patients with LN were classified with type VI disease [<a href="#rid117">117</a>]. Identification of this lesion is important since immunosuppressive therapy is unlikely to be beneficial.</p><p class="headingAnchor" id="H1548573987"><span class="h3">Activity and chronicity</span><span class="headingEndMark"> — </span>Most biopsies of patients with LN are classified not only by LN class but also with an index of "activity" and of "chronicity."</p><p class="bulletIndent1"><span class="glyph">●</span>Active lesions are generally inflammatory or proliferative and potentially reversible. These include endocapillary hypercellularity, neutrophils and karyorrhexis, fibrinoid necrosis, hyaline wire loops, cellular or fibrocellular crescents, and interstitial inflammation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic lesions imply irreversible damage and would not generally mandate immunosuppression. These include glomerulosclerosis, fibrous crescents, interstitial fibrosis, and tubular atrophy.</p><p></p><p>The activity and chronicity indices are defined by a summation of scoring of the above findings weighted for more severe components.</p><p class="headingAnchor" id="H645553610"><span class="h1">OTHER FORMS OF LUPUS KIDNEY DISEASE</span><span class="headingEndMark"> — </span>In addition to the glomerulopathies, there are other forms of lupus kidney disease, including tubulointerstitial nephritis, vascular disease, lupus podocytopathy, collapsing glomerulosclerosis, and kidney disease infrequently associated with drug-induced lupus [<a href="#rid5">5</a>]. Many of these patterns of kidney damage can only be diagnosed with a biopsy. The investigators responsible for the International Society of Nephrology/Renal Pathologic Society (ISN/RPS) classification system of lupus nephritis (LN) emphasize that the presence and severity of tubulointerstitial and vascular involvement should be noted in any biopsy specimen [<a href="#rid93">93,94,96</a>].</p><p class="headingAnchor" id="H3011549783"><span class="h2">Tubulointerstitial lesions</span><span class="headingEndMark"> — </span>Tubulointerstitial disease (interstitial infiltrate, tubular injury) with or without immune deposits along the tubular basement membrane is a common finding in LN and is almost always associated with concurrent glomerular disease [<a href="#rid118">118,119</a>]. The severity of the tubulointerstitial involvement is an important prognostic sign, correlating positively with the presence of hypertension, an elevated plasma creatinine concentration, and a progressive clinical course [<a href="#rid119">119-121</a>]. In a study of 313 patients with LN, for example, the presence of tubulointerstitial nephritis was significantly associated with a twofold higher risk of developing end-stage kidney disease (ESKD) or a doubling of serum creatinine after controlling for other prognostic indicators [<a href="#rid121">121</a>]. As expected, both tubular atrophy and interstitial fibrosis were also associated with an increased risk. By contrast, the presence of tubular basement membrane deposits alone correlates with the serologic activity of the disease but not the prognosis [<a href="#rid119">119</a>].</p><p>In a few cases, tubulointerstitial disease is the only manifestation of LN. This possibility should be suspected when a patient with systemic lupus erythematosus (SLE) presents with a rising plasma creatinine concentration and a urinalysis that is relatively normal or shows only a few red cells and/or white cells [<a href="#rid122">122,123</a>]. These changes may be accompanied by signs of tubular dysfunction such as metabolic acidosis due to type 1 (distal) renal tubular acidosis, hyperkalemia due to impaired distal potassium secretion, or hypokalemia due to salt wasting and secondary hyperaldosteronism [<a href="#rid124">124,125</a>]. Idiopathic hypokalemia distinct from that associated with renal tubular acidosis has also been observed in a small cohort of patients with LN [<a href="#rid126">126</a>]. Autoantibodies directed against the acid-secreting intercalated cells in the collecting tubule may be responsible for the acid secretory defect in at least some patients [<a href="#rid127">127</a>]. A review of the mechanisms by which distal acid secretion can be altered is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2327.html" rel="external">"Overview and pathophysiology of renal tubular acidosis and the effect on potassium balance"</a>.)</p><p class="headingAnchor" id="H2792392866"><span class="h2">Vascular lesions</span><span class="headingEndMark"> — </span>Involvement of the kidney vasculature is not uncommon in LN, and its presence can adversely affect the prognosis of the kidney disease [<a href="#rid117">117,128,129</a>]. The most frequent manifestations are immune complex deposition (which is typically associated with immune deposits in the glomeruli), immunoglobulin microvascular "thrombi," a thrombotic microangiopathy leading to a syndrome similar to thrombotic thrombocytopenic purpura (TTP), vasculitis, or atheroembolic disease and atherosclerosis [<a href="#rid117">117,128,130-132</a>].</p><p>Vascular immune deposits are usually located beneath an intact endothelium. They typically produce no inflammation; however, fibrinoid necrosis with vascular narrowing can be seen in severe cases, often in association with moderate to severe hypertension [<a href="#rid129">129</a>]. It is unclear in this setting whether the hypertension contributes to the vascular injury and/or whether the vascular narrowing exacerbates the hypertension via activation of the renin-angiotensin system. Regardless of the pathogenesis, patients with necrotizing vasculopathy tend to have a worse kidney prognosis than those with isolated glomerular disease.</p><p>Rarely, patients with LN develop renal vein thrombosis [<a href="#rid133">133</a>]. These patients are typically nephrotic or have high antiphospholipid antibody levels, and the pathogenesis and treatment of the renal vein thrombosis are similar to that in patients without SLE. (See  <a class="medical medical_review" href="/z/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome"</a>.)</p><p>Other patients present with glomerular and vascular thrombi. These lesions may involve a diverse group of thrombotic microangiopathies [<a href="#rid132">132</a>]. Some are in association with antiphospholipid antibodies such as the lupus anticoagulant (LA) and anticardiolipin antibodies, or antibodies against the von Willebrand factor convertase (ADAMTS13). The name "LA" refers to the ability of these antibodies to produce in vitro prolongation of the partial thromboplastin time. In vivo, however, antiphospholipid antibodies promote coagulation, leading to venous and arterial thromboses, thrombocytopenia, livedo reticularis, and in women, frequent miscarriages. (See  <a class="medical medical_review" href="/z/d/html/3073.html" rel="external">"Antiphospholipid syndrome and the kidney"</a>.)</p><p class="headingAnchor" id="H518285291"><span class="h2">Lupus podocytopathy</span><span class="headingEndMark"> — </span>Some investigators have demonstrated that a glomerular podocytopathy due to kidney involvement in lupus can be associated with diffuse epithelial cell foot process effacement without immune complex deposition. This is the classic histologic finding of minimal change disease [<a href="#rid134">134-136</a>]. It is estimated such lesions occur in 1 to 2 percent of nephrotic patients with SLE [<a href="#rid5">5,137</a>]. Such lesions have been termed "lupus podocytopathy" [<a href="#rid138">138</a>]. In a retrospective study of 470 kidney biopsies from patients with SLE, biopsies with normal light microscopy or a histologic diagnosis of either focal segmental glomerulosclerosis or mesangial proliferative glomerulonephritis were further evaluated [<a href="#rid134">134</a>]. The absence of endocapillary hypercellularity or necrosis, or of electron-dense glomerular basement membrane deposits, was found in 18 such biopsies, of which eight were from patients with nephrotic-range proteinuria. At least 80 percent foot process effacement was observed in all but one of these eight patients.</p><p>There is a possibility that these observations reflect the chance occurrence of SLE and either minimal change nephropathy and/or focal segmental glomerulosclerosis. However, this should occur in less than 1 in 10,000 cases, a frequency that is much less than that observed in this study (7 of 470). In addition, the onset of podocytopathy in these patients is seen most commonly at the onset of SLE or in the setting of a disease flare.</p><p>The presence of severe foot process effacement in the absence of deposits in the glomerular capillary wall implies a mechanism that is independent of immune complex deposition, presumably similar to the mechanism of primary minimal change disease or primary focal segmental glomerulosclerosis. Proposed explanations include direct antibody binding to podocyte slit diaphragm proteins, production of a cytokine or lymphokine toxic to podocytes, or podocyte injury driven by T cell dysfunction. A number of lupus podocytopathy cases have been linked to nonsteroidal antiinflammatory drug (NSAID) use for SLE [<a href="#rid134">134,136,138</a>].</p><p>Patients with a lupus-related podocytopathy often respond to a short course of high-dose glucocorticoids, similar to patients with isolated minimal change disease [<a href="#rid139">139</a>]. (See  <a class="medical medical_review" href="/z/d/html/3045.html" rel="external">"Minimal change disease: Treatment in adults"</a>.)</p><p class="headingAnchor" id="H3099118994"><span class="h2">Collapsing glomerulosclerosis</span><span class="headingEndMark"> — </span>Collapsing glomerulosclerosis is histologically characterized by the collapse of the glomerular capillary tuft with epithelial cell proliferation in the Bowman's space and is clinically characterized by the nephrotic syndrome, kidney function impairment, and rapid progression to ESKD. Collapsing glomerulosclerosis is most often associated with HIV or COVID-19-associated nephropathy, especially in patients of African descent with two risk alleles for <em>APOL1</em>. However, collapsing glomerulosclerosis can also be seen in patients with SLE, usually during an active flare [<a href="#rid140">140</a>]. In addition, such patients may have concurrent LN. These issues are described in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3080.html" rel="external">"Collapsing focal segmental glomerulosclerosis (collapsing glomerulopathy)"</a>.)</p><p class="headingAnchor" id="H4160172713"><span class="h2">Drug-induced lupus</span><span class="headingEndMark"> — </span>A variety of drugs can induce a lupus-like syndrome, such as <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>, <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>, and historically, <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>. Kidney involvement is an uncommon feature of drug-induced lupus, but a proliferative glomerulonephritis or the nephrotic syndrome can occur. (See  <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">"Drug-induced lupus"</a>.)</p><p class="headingAnchor" id="H1727799961"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/110740.html" rel="external">"Society guideline links: Systemic lupus erythematosus"</a>.)</p><p class="headingAnchor" id="H3717610203"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/86553.html" rel="external">"Patient education: Lupus and kidney disease (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3429360314"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– Most patients with systemic lupus erythematosus (SLE) will have clinical evidence of kidney disease, usually an abnormal urinalysis, at some point in the course of their disease. When present, lupus nephritis (LN) typically develops earlier in the disease course. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– Although LN is considered to be a classic form of immune complex glomerulonephritis, the pathogenesis of LN can involve a variety of mechanisms. These mechanisms include the expression of genes leading to neutrophil activation, increased expression of genes for interferon and other pro-inflammatory mediators in myeloid and other immune cell populations, release of neutrophil extracellular traps (NETs), and complement activation. The pattern of glomerular injury seen in SLE (and in other immune complex-mediated glomerular diseases) is generally related to the site of formation of the immune deposits, which are primarily due to anti-double-stranded DNA (anti-dsDNA or anti-DNA) antibodies. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– Kidney disease is typically detected in most patients with SLE by an abnormal urinalysis with or without an elevated plasma creatinine concentration. The most frequently observed abnormality in patients with LN is proteinuria. Other common clinical manifestations include microscopic hematuria with or without red cell casts, kidney function impairment, nephrotic-range proteinuria or nephrotic syndrome, and hypertension. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to suspect LN </strong>– The presence of LN should be suspected in patients with known SLE who develop an active urinary sediment with persistent hematuria (five or more red blood cells, most of which are dysmorphic, per high-power field) and/or cellular casts, proteinuria, and/or an elevated serum creatinine (or decrease in estimated glomerular filtration rate [eGFR]). Elevated anti-dsDNA titers and low complement (C3 and C4) levels often indicate active SLE, particularly LN, although the utility of serological assessment differs among patients. There are some patients for whom signs and symptoms of LN are the predominant presenting symptoms resulting in the diagnosis of SLE. (See <a class="local">'When to suspect LN'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of LN is ideally confirmed by histologic findings in a kidney biopsy. A kidney biopsy is important to define the nature of kidney involvement, exclude other causes of kidney injury, and determine the histopathologic subtype of LN. Biopsies are also important to assess disease activity and chronicity. (See <a class="local">'Establishing the diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathologic classification </strong>– A widely used classification system of LN divides glomerular disorders associated with SLE into six different patterns or classes based upon kidney biopsy findings including minimal mesangial LN (class I), mesangial proliferative LN (class II), focal LN (class III), diffuse LN (class IV), lupus membranous nephropathy (class V), and advanced sclerosing LN (class VI). (See <a class="local">'Histopathologic classification of LN'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other forms of lupus kidney disease </strong>– In addition to the glomerulopathies, there are other forms of lupus kidney disease, including tubulointerstitial nephritis, vascular disease (including thrombotic microangiopathy), lupus podocytopathy, collapsing glomerulosclerosis, and kidney disease infrequently associated with drug-induced lupus. Many of these patterns of kidney damage can only be diagnosed with a biopsy. (See <a class="local">'Other forms of lupus kidney disease'</a> above.)</p><p></p><p class="headingAnchor" id="H2259325136"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Peter H Schur, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol 2017; 12:825.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:S1.</a></li><li><a class="nounderline abstract_t">Rojas-Rivera JE, García-Carro C, Ávila AI, et al. Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN). Clin Kidney J 2023; 16:1384.</a></li><li><a class="nounderline abstract_t">Ortega LM, Schultz DR, Lenz O, et al. Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 2010; 19:557.</a></li><li><a class="nounderline abstract_t">Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on Lupus Nephritis: Core Curriculum 2020. Am J Kidney Dis 2020; 76:265.</a></li><li><a class="nounderline abstract_t">Lim SS, Bayakly AR, Helmick CG, et al. The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry. Arthritis Rheumatol 2014; 66:357.</a></li><li><a class="nounderline abstract_t">Somers EC, Marder W, Cagnoli P, et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol 2014; 66:369.</a></li><li><a class="nounderline abstract_t">Izmirly PM, Wan I, Sahl S, et al. The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. Arthritis Rheumatol 2017; 69:2006.</a></li><li><a class="nounderline abstract_t">Dall'Era M, Cisternas MG, Snipes K, et al. The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project. Arthritis Rheumatol 2017; 69:1996.</a></li><li><a class="nounderline abstract_t">O'Flynn J, Flierman R, van der Pol P, et al. Nucleosomes and C1q bound to glomerular endothelial cells serve as targets for autoantibodies and determine complement activation. Mol Immunol 2011; 49:75.</a></li><li><a class="nounderline abstract_t">Alarcón GS. Multiethnic lupus cohorts: what have they taught us? Reumatol Clin 2011; 7:3.</a></li><li><a class="nounderline abstract_t">Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993; 72:113.</a></li><li><a class="nounderline abstract_t">Seligman VA, Lum RF, Olson JL, et al. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med 2002; 112:726.</a></li><li><a class="nounderline abstract_t">Wang F, Wang CL, Tan CT, Manivasagar M. Systemic lupus erythematosus in Malaysia: a study of 539 patients and comparison of prevalence and disease expression in different racial and gender groups. Lupus 1997; 6:248.</a></li><li><a class="nounderline abstract_t">Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82:299.</a></li><li><a class="nounderline abstract_t">Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 2006; 85:147.</a></li><li><a class="nounderline abstract_t">To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum 2005; 52:4003.</a></li><li><a class="nounderline abstract_t">Alarcón GS, McGwin G Jr, Petri M, et al. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus 2002; 11:95.</a></li><li><a class="nounderline abstract_t">Hanly JG, O'Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 2016; 55:252.</a></li><li><a class="nounderline abstract_t">Bastian HM, Roseman JM, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002; 11:152.</a></li><li><a class="nounderline abstract_t">Feldman CH, Hiraki LT, Liu J, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum 2013; 65:753.</a></li><li><a class="nounderline abstract_t">Contreras G, Lenz O, Pardo V, et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006; 69:1846.</a></li><li><a class="nounderline abstract_t">Barr RG, Seliger S, Appel GB, et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant 2003; 18:2039.</a></li><li><a class="nounderline abstract_t">Rovin BH, Caster DJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019; 95:281.</a></li><li><a class="nounderline abstract_t">Banchereau R, Hong S, Cantarel B, et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell 2016; 165:551.</a></li><li><a class="nounderline abstract_t">Arazi A, Rao DA, Berthier CC, et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol 2019; 20:902.</a></li><li><a class="nounderline abstract_t">Der E, Suryawanshi H, Morozov P, et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol 2019; 20:915.</a></li><li><a class="nounderline abstract_t">Villanueva E, Yalavarthi S, Berthier CC, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011; 187:538.</a></li><li><a class="nounderline abstract_t">Hakkim A, Fürnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A 2010; 107:9813.</a></li><li><a class="nounderline abstract_t">Birmingham DJ, Bitter JE, Ndukwe EG, et al. Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare. Clin J Am Soc Nephrol 2016; 11:47.</a></li><li><a class="nounderline abstract_t">Kashgarian M. Lupus nephritis: lessons from the path lab. Kidney Int 1994; 45:928.</a></li><li><a class="nounderline abstract_t">Fries JW, Mendrick DL, Rennke HG. Determinants of immune complex-mediated glomerulonephritis. Kidney Int 1988; 34:333.</a></li><li><a class="nounderline abstract_t">Hulsey M, Goldstein R, Scully L, et al. Anti-ribosomal P antibodies in systemic lupus erythematosus: a case-control study correlating hepatic and renal disease. Clin Immunol Immunopathol 1995; 74:252.</a></li><li><a class="nounderline abstract_t">Ben-Yehuda A, Rasooly L, Bar-Tana R, et al. The urine of SLE patients contains antibodies that bind to the laminin component of the extracellular matrix. J Autoimmun 1995; 8:279.</a></li><li><a class="nounderline abstract_t">Akashi Y, Yoshizawa N. Participation of histones and ubiquitin in lupus nephritis. Nihon Jinzo Gakkai Shi 1995; 37:462.</a></li><li><a class="nounderline abstract_t">Lefkowith JB, Gilkeson GS. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum 1996; 39:894.</a></li><li><a class="nounderline abstract_t">Mannik M, Merrill CE, Stamps LD, Wener MH. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol 2003; 30:1495.</a></li><li><a class="nounderline abstract_t">Yin Y, Wu X, Shan G, Zhang X. Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis. Lupus 2012; 21:1088.</a></li><li><a class="nounderline abstract_t">Ronco P, Debiec H. Molecular Pathogenesis of Membranous Nephropathy. Annu Rev Pathol 2020; 15:287.</a></li><li><a class="nounderline abstract_t">Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996; 39:9.</a></li><li><a class="nounderline abstract_t">Malide D, Russo P, Bendayan M. Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 1995; 26:558.</a></li><li><a class="nounderline abstract_t">Bergijk EC, de Heer E, Hoedemaeker PJ, Bruijn JA. A reappraisal of immune-mediated glomerulosclerosis. Kidney Int 1996; 49:605.</a></li><li><a class="nounderline abstract_t">Balomenos D, Rumold R, Theofilopoulos AN. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 1998; 101:364.</a></li><li><a class="nounderline abstract_t">Vielhauer V, Anders HJ, Schlöndorff D. Chemokines and chemokine receptors as therapeutic targets in lupus nephritis. Semin Nephrol 2007; 27:81.</a></li><li><a class="nounderline abstract_t">Delmas Y, Viallard JF, Solanilla A, et al. Activation of mesangial cells by platelets in systemic lupus erythematosus via a CD154-dependent induction of CD40. Kidney Int 2005; 68:2068.</a></li><li><a class="nounderline abstract_t">Seelen MA, Trouw LA, Daha MR. Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens 2003; 12:619.</a></li><li><a class="nounderline abstract_t">Horváth L, Czirják L, Fekete B, et al. High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin Exp Rheumatol 2001; 19:667.</a></li><li><a class="nounderline abstract_t">Marto N, Bertolaccini ML, Calabuig E, et al. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005; 64:444.</a></li><li><a class="nounderline abstract_t">Trouw LA, Groeneveld TW, Seelen MA, et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004; 114:679.</a></li><li><a class="nounderline abstract_t">Du H, Chen M, Zhang Y, et al. Cross-reaction of anti-DNA autoantibodies with membrane proteins of human glomerular mesangial cells in sera from patients with lupus nephritis. Clin Exp Immunol 2006; 145:21.</a></li><li><a class="nounderline abstract_t">Yung S, Tsang RC, Leung JK, Chan TM. Increased mesangial cell hyaluronan expression in lupus nephritis is mediated by anti-DNA antibody-induced IL-1beta. Kidney Int 2006; 69:272.</a></li><li><a class="nounderline abstract_t">Espeli M, Bökers S, Giannico G, et al. Local renal autoantibody production in lupus nephritis. J Am Soc Nephrol 2011; 22:296.</a></li><li><a class="nounderline abstract_t">Munroe ME, James JA. Genetics of Lupus Nephritis: Clinical Implications. Semin Nephrol 2015; 35:396.</a></li><li><a class="nounderline abstract_t">Niu Z, Zhang P, Tong Y. Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis. Int J Rheum Dis 2015; 18:17.</a></li><li><a class="nounderline abstract_t">Chung SA, Brown EE, Williams AH, et al. Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. J Am Soc Nephrol 2014; 25:2859.</a></li><li><a class="nounderline abstract_t">Salmon JE, Millard S, Schachter LA, et al. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996; 97:1348.</a></li><li><a class="nounderline abstract_t">Karassa FB, Trikalinos TA, Ioannidis JP, FcgammaRIIa-SLE Meta-Analysis Investigators. Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum 2002; 46:1563.</a></li><li><a class="nounderline abstract_t">Karassa FB, Trikalinos TA, Ioannidis JP, Fc gamma RIIIA-SLE meta-analysis investigators. The Fc gamma RIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis. Kidney Int 2003; 63:1475.</a></li><li><a class="nounderline abstract_t">Aitman TJ, Dong R, Vyse TJ, et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006; 439:851.</a></li><li><a class="nounderline abstract_t">Gelmetti AP, Freitas AC, Woronik V, et al. Polymorphism of the FcgammaRIIalpha IgG receptor in patients with lupus nephritis and glomerulopathy. J Rheumatol 2006; 33:523.</a></li><li><a class="nounderline abstract_t">Morel L. Genetics of human lupus nephritis. Semin Nephrol 2007; 27:2.</a></li><li><a class="nounderline abstract_t">Freedman BI, Langefeld CD, Andringa KK, et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 2014; 66:390.</a></li><li><a class="nounderline abstract_t">Larsen CP, Beggs ML, Saeed M, Walker PD. Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. J Am Soc Nephrol 2013; 24:722.</a></li><li><a class="nounderline abstract_t">Parikh SV, Rovin BH. Current and Emerging Therapies for Lupus Nephritis. J Am Soc Nephrol 2016; 27:2929.</a></li><li><a class="nounderline abstract_t">Nossent HC, Henzen-Logmans SC, Vroom TM, et al. Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients. Arthritis Rheum 1990; 33:970.</a></li><li><a class="nounderline abstract_t">Anders HJ, Saxena R, Zhao MH, et al. Lupus nephritis. Nat Rev Dis Primers 2020; 6:7.</a></li><li><a class="nounderline abstract_t">Gonzalez-Crespo MR, Lopez-Fernandez JI, Usera G, et al. Outcome of silent lupus nephritis. Semin Arthritis Rheum 1996; 26:468.</a></li><li><a class="nounderline abstract_t">Wada Y, Ito S, Ueno M, et al. Renal outcome and predictors of clinical renal involvement in patients with silent lupus nephritis. Nephron Clin Pract 2004; 98:c105.</a></li><li><a class="nounderline abstract_t">Zabaleta-Lanz ME, Muñoz LE, Tapanes FJ, et al. Further description of early clinically silent lupus nephritis. Lupus 2006; 15:845.</a></li><li><a class="nounderline abstract_t">Wakasugi D, Gono T, Kawaguchi Y, et al. Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures. J Rheumatol 2012; 39:79.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int 2024; 105:S1.</a></li><li><a class="nounderline abstract_t">Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020; 79:713.</a></li><li><a class="nounderline abstract_t">Wang S, Spielman A, Ginsberg M, et al. Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria. Clin J Am Soc Nephrol 2022; 17:1150.</a></li><li><a class="nounderline abstract_t">Lee LC, Lam KK, Lee CT, et al. "Full house" proliferative glomerulonephritis: an unreported presentation of subacute infective endocarditis. J Nephrol 2007; 20:745.</a></li><li><a class="nounderline abstract_t">Haas M, Kaul S, Eustace JA. HIV-associated immune complex glomerulonephritis with "lupus-like" features: a clinicopathologic study of 14 cases. Kidney Int 2005; 67:1381.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Font J, García-Carrasco M, et al. Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. Arthritis Rheum 2000; 43:2801.</a></li><li><a class="nounderline abstract_t">Smet AD, Kuypers D, Evenepoel P, et al. 'Full house' positive immunohistochemical membranoproliferative glomerulonephritis in a patient with portosystemic shunt. Nephrol Dial Transplant 2001; 16:2258.</a></li><li><a class="nounderline abstract_t">Kudose S, Santoriello D, Bomback AS, et al. Sensitivity and Specificity of Pathologic Findings to Diagnose Lupus Nephritis. Clin J Am Soc Nephrol 2019; 14:1605.</a></li><li><a class="nounderline abstract_t">Rich SA. De novo synthesis and secretion of a 36-kD protein by cells that form lupus inclusions in response to alpha-interferon. J Clin Invest 1995; 95:219.</a></li><li><a class="nounderline abstract_t">Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol 2006; 33:1563.</a></li><li><a class="nounderline abstract_t">Esdaile JM, Joseph L, MacKenzie T, et al. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol 1994; 21:2046.</a></li><li><a class="nounderline abstract_t">Contreras G, Pardo V, Cely C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005; 14:890.</a></li><li><a class="nounderline abstract_t">Mercadal L, Montcel ST, Nochy D, et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant 2002; 17:1771.</a></li><li><a class="nounderline abstract_t">Huong DL, Papo T, Beaufils H, et al. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine (Baltimore) 1999; 78:148.</a></li><li><a class="nounderline abstract_t">Moroni G, Pasquali S, Quaglini S, et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis 1999; 34:530.</a></li><li><a class="nounderline abstract_t">Bajaj S, Albert L, Gladman DD, et al. Serial renal biopsy in systemic lupus erythematosus. J Rheumatol 2000; 27:2822.</a></li><li><a class="nounderline abstract_t">Austin HA 3rd, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009; 20:901.</a></li><li><a class="nounderline abstract_t">Alvarado AS, Malvar A, Lococo B, et al. The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. Lupus 2014; 23:840.</a></li><li><a class="nounderline abstract_t">Malvar A, Pirruccio P, Alberton V, et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant 2017; 32:1338.</a></li><li><a class="nounderline abstract_t">Malvar A, Alberton V, Lococo B, et al. Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. Kidney Int 2020; 97:156.</a></li><li><a class="nounderline abstract_t">Morales E, Trujillo H, Bada T, et al. What is the value of repeat kidney biopsies in patients with lupus nephritis? Lupus 2021; 30:25.</a></li><li><a class="nounderline abstract_t">De Rosa M, Azzato F, Toblli JE, et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int 2018; 94:788.</a></li><li><a class="nounderline abstract_t">Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65:521.</a></li><li><a class="nounderline abstract_t">Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15:241.</a></li><li><a class="nounderline abstract_t">Furness PN, Taub N. Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis-a UK-wide study. Am J Surg Pathol 2006; 30:1030.</a></li><li><a class="nounderline abstract_t">Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 2018; 93:789.</a></li><li><a class="nounderline abstract_t">Appel GB, Silva FG, Pirani CL, et al. Renal involvement in systemic lupud erythematosus (SLE): a study of 56 patients emphasizing histologic classification. Medicine (Baltimore) 1978; 57:371.</a></li><li><a class="nounderline abstract_t">Lee HS, Mujais SK, Kasinath BS, et al. Course of renal pathology in patients with systemic lupus erythematosus. Am J Med 1984; 77:612.</a></li><li><a class="nounderline abstract_t">Najafi CC, Korbet SM, Lewis EJ, et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001; 59:2156.</a></li><li><a class="nounderline abstract_t">Lu J, Tam LS, Lai FM, et al. Repeat renal biopsy in lupus nephritis: a change in histological pattern is common. Am J Nephrol 2011; 34:220.</a></li><li><a class="nounderline abstract_t">Rovin BH, Zhang X. Biomarkers for lupus nephritis: the quest continues. Clin J Am Soc Nephrol 2009; 4:1858.</a></li><li><a class="nounderline abstract_t">Coremans IE, Spronk PE, Bootsma H, et al. Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis 1995; 26:595.</a></li><li><a class="nounderline abstract_t">Schwartz N, Rubinstein T, Burkly LC, et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009; 11:R143.</a></li><li><a class="nounderline abstract_t">Rubinstein T, Pitashny M, Levine B, et al. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) 2010; 49:960.</a></li><li><a class="nounderline abstract_t">Schwartz MM, Kawala KS, Corwin HL, Lewis EJ. The prognosis of segmental glomerulonephritis in systemic lupus erythematosus. Kidney Int 1987; 32:274.</a></li><li><a class="nounderline abstract_t">Schwartz MM, Lan SP, Bonsib SM, et al. Clinical outcome of three discrete histologic patterns of injury in severe lupus glomerulonephritis. Am J Kidney Dis 1989; 13:273.</a></li><li><a class="nounderline abstract_t">Lloyd W, Schur PH. Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore) 1981; 60:208.</a></li><li><a class="nounderline abstract_t">Akashi Y, Oshima S, Takeuchi A, et al. [Identification and analysis of immune cells infiltrating into the glomerulus and interstitium in lupus nephritis]. Nihon Rinsho Meneki Gakkai Kaishi 1995; 18:545.</a></li><li><a class="nounderline abstract_t">Davis JC, Tassiulas IO, Boumpas DT. Lupus nephritis. Curr Opin Rheumatol 1996; 8:415.</a></li><li><a class="nounderline abstract_t">Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999; 10:413.</a></li><li><a class="nounderline abstract_t">Donadio JV Jr, Burgess JH, Holley KE. Membranous lupus nephropathy: a clinicopathologic study. Medicine (Baltimore) 1977; 56:527.</a></li><li><a class="nounderline abstract_t">Jennette JC, Iskandar SS, Dalldorf FG. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int 1983; 24:377.</a></li><li><a class="nounderline abstract_t">Adu D, Williams DG, Taube D, et al. Late onset systemic lupus erythematosus and lupus-like disease in patients with apparent idiopathic glomerulonephritis. Q J Med 1983; 52:471.</a></li><li><a class="nounderline abstract_t">Sun HO, Hu WX, Xie HL, et al. Long-term outcome of Chinese patients with membranous lupus nephropathy. Lupus 2008; 17:56.</a></li><li><a class="nounderline abstract_t">Beck LH Jr, Salant DJ. Treatment of membranous lupus nephritis: where are we now? J Am Soc Nephrol 2009; 20:690.</a></li><li><a class="nounderline abstract_t">Sloan RP, Schwartz MM, Korbet SM, Borok RZ. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol 1996; 7:299.</a></li><li><a class="nounderline abstract_t">Descombes E, Droz D, Drouet L, et al. Renal vascular lesions in lupus nephritis. Medicine (Baltimore) 1997; 76:355.</a></li><li><a class="nounderline abstract_t">Brentjens JR, Sepulveda M, Baliah T, et al. Interstitial immune complex nephritis in patients with systemic lupus erythematosus. Kidney Int 1975; 7:342.</a></li><li><a class="nounderline abstract_t">Park MH, D'Agati V, Appel GB, Pirani CL. Tubulointerstitial disease in lupus nephritis: relationship to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis. Nephron 1986; 44:309.</a></li><li><a class="nounderline abstract_t">Alexopoulos E, Seron D, Hartley RB, Cameron JS. Lupus nephritis: correlation of interstitial cells with glomerular function. Kidney Int 1990; 37:100.</a></li><li><a class="nounderline abstract_t">Yu F, Wu LH, Tan Y, et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int 2010; 77:820.</a></li><li><a class="nounderline abstract_t">Tron F, Ganeval D, Droz D. Immunologically-mediated acute renal failure of nonglomerular origin in the course of systemic lupus erythematosus [SLE]. Report of two cases. Am J Med 1979; 67:529.</a></li><li><a class="nounderline abstract_t">Singh AK, Ucci A, Madias NE. Predominant tubulointerstitial lupus nephritis. Am J Kidney Dis 1996; 27:273.</a></li><li><a class="nounderline abstract_t">Kozeny GA, Barr W, Bansal VK, et al. Occurrence of renal tubular dysfunction in lupus nephritis. Arch Intern Med 1987; 147:891.</a></li><li><a class="nounderline abstract_t">DeFronzo RA, Cooke CR, Goldberg M, et al. Impaired renal tubular potassium secretion in systemic lupus erythematosus. Ann Intern Med 1977; 86:268.</a></li><li><a class="nounderline abstract_t">Adomako EA, Bilal S, Liu YL, et al. Idiopathic Hypokalemia in Lupus Nephritis: A Newly Recognized Entity. Kidney360 2021; 2:1553.</a></li><li><a class="nounderline abstract_t">Bastani B, Underhill D, Chu N, et al. Preservation of intercalated cell H(+)-ATPase in two patients with lupus nephritis and hyperkalemic distal renal tubular acidosis. J Am Soc Nephrol 1997; 8:1109.</a></li><li><a class="nounderline abstract_t">Wu LH, Yu F, Tan Y, et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int 2013; 83:715.</a></li><li><a class="nounderline abstract_t">Appel GB, Pirani CL, D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 1994; 4:1499.</a></li><li><a class="nounderline abstract_t">Abdellatif AA, Waris S, Lakhani A, et al. True vasculitis in lupus nephritis. Clin Nephrol 2010; 74:106.</a></li><li><a class="nounderline abstract_t">Kwok SK, Ju JH, Cho CS, et al. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study. Lupus 2009; 18:16.</a></li><li><a class="nounderline abstract_t">Song D, Wu LH, Wang FM, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 2013; 15:R12.</a></li><li><a class="nounderline abstract_t">Gelfand J, Truong L, Stern L, et al. Thrombotic thrombocytopenic purpura syndrome in systemic lupus erythematosus: treatment with plasma infusion. Am J Kidney Dis 1985; 6:154.</a></li><li><a class="nounderline abstract_t">Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol 2005; 16:175.</a></li><li><a class="nounderline abstract_t">Hu W, Chen Y, Wang S, et al. Clinical-Morphological Features and Outcomes of Lupus Podocytopathy. Clin J Am Soc Nephrol 2016; 11:585.</a></li><li><a class="nounderline abstract_t">Dube GK, Markowitz GS, Radhakrishnan J, et al. Minimal change disease in systemic lupus erythematosus. Clin Nephrol 2002; 57:120.</a></li><li><a class="nounderline abstract_t">Oliva-Damaso N, Payan J, Oliva-Damaso E, et al. Lupus Podocytopathy: An Overview. Adv Chronic Kidney Dis 2019; 26:369.</a></li><li><a class="nounderline abstract_t">Shea-Simonds P, Cairns TD, Roufosse C, et al. Lupus podocytopathy. Rheumatology (Oxford) 2009; 48:1616.</a></li><li><a class="nounderline abstract_t">Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol 2010; 21:2028.</a></li><li><a class="nounderline abstract_t">Salvatore SP, Barisoni LM, Herzenberg AM, et al. Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease. Clin J Am Soc Nephrol 2012; 7:914.</a></li></ol></div><div id="topicVersionRevision">Topic 3056 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27821390" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Update on Lupus Nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34556256" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37664575" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089610" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32220510" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Update on Lupus Nephritis: Core Curriculum 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24504808" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24504809" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28891252" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28891237" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21855148" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Nucleosomes and C1q bound to glomerular endothelial cells serve as targets for autoantibodies and determine complement activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21794772" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Multiethnic lupus cohorts: what have they taught us?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8479324" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12079714" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Demographic differences in the development of lupus nephritis: a retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9104731" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Systemic lupus erythematosus in Malaysia: a study of 539 patients and comparison of prevalence and disease expression in different racial and gender groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14530779" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16721257" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Predictors of survival in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16320348" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11958584" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Baseline characteristics of a multiethnic lupus cohort: PROFILE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26342222" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The frequency and outcome of lupus nephritis: results from an international inception cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12004788" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23203603" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16598205" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Outcomes in African Americans and Hispanics with lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13679478" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30665569" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27040498" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31209404" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The immune cell landscape in kidneys of patients with lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31110316" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21613614" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439745" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26700439" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8196299" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Lupus nephritis: lessons from the path lab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2971836" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Determinants of immune complex-mediated glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7859415" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Anti-ribosomal P antibodies in systemic lupus erythematosus: a case-control study correlating hepatic and renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7612153" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The urine of SLE patients contains antibodies that bind to the laminin component of the extracellular matrix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7563955" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Participation of histones and ubiquitin in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8651982" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nephritogenic autoantibodies in lupus: current concepts and continuing controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12858447" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22777943" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31622560" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Molecular Pathogenesis of Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8546744" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7750940" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8648899" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A reappraisal of immune-mediated glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9435308" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17336691" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Chemokines and chemokine receptors as therapeutic targets in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16221206" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Activation of mesangial cells by platelets in systemic lupus erythematosus via a CD154-dependent induction of CD40.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14564199" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11791638" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15286009" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15343386" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16792669" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cross-reaction of anti-DNA autoantibodies with membrane proteins of human glomerular mesangial cells in sera from patients with lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16408116" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Increased mesangial cell hyaluronan expression in lupus nephritis is mediated by anti-DNA antibody-induced IL-1beta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21088295" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Local renal autoantibody production in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26573543" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Genetics of Lupus Nephritis: Clinical Implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25546242" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24925725" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Lupus nephritis susceptibility loci in women with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636449" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12115187" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12631364" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The Fc gamma RIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16482158" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16511922" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Polymorphism of the FcgammaRIIalpha IgG receptor in patients with lupus nephritis and glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17336684" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Genetics of human lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24504811" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : End-stage renal disease in African Americans with lupus nephritis is associated with APOL1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23520206" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27283496" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Current and Emerging Therapies for Lupus Nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2369432" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31974366" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8870114" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Outcome of silent lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15627787" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Renal outcome and predictors of clinical renal involvement in patients with silent lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17211989" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Further description of early clinically silent lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22089455" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38182286" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32220834" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35882508" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18046678" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : "Full house" proliferative glomerulonephritis: an unreported presentation of subacute infective endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15780090" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : HIV-associated immune complex glomerulonephritis with "lupus-like" features: a clinicopathologic study of 14 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11145039" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11682680" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : 'Full house' positive immunohistochemical membranoproliferative glomerulonephritis in a patient with portosystemic shunt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31653670" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Sensitivity and Specificity of Pathologic Findings to Diagnose Lupus Nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7814619" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : De novo synthesis and secretion of a 36-kD protein by cells that form lupus inclusions in response to alpha-interferon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16881113" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7869308" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The benefit of early treatment with immunosuppressive agents in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16335581" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Factors associated with poor outcomes in patients with lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12270983" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Factors affecting outcome and prognosis in membranous lupus nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10352647" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10469865" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Clinical and prognostic value of serial renal biopsies in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11128670" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Serial renal biopsy in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19297556" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24401872" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26250434" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Histologic versus clinical remission in proliferative lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31685314" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33081588" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : What is the value of repeat kidney biopsies in patients with lupus nephritis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30045812" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14717922" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The classification of glomerulonephritis in systemic lupus erythematosus revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747370" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The classification of glomerulonephritis in systemic lupus erythematosus revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16861976" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis-a UK-wide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29459092" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/682942" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Renal involvement in systemic lupud erythematosus (SLE): a study of 56 patients emphasizing histologic classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6486137" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Course of renal pathology in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11380817" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21791918" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Repeat renal biopsy in lupus nephritis: a change in histological pattern is common.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19729426" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Biomarkers for lupus nephritis: the quest continues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7573013" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19785730" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20144927" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3656940" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The prognosis of segmental glomerulonephritis in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2650538" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Clinical outcome of three discrete histologic patterns of injury in severe lupus glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7231154" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8564699" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : [Identification and analysis of immune cells infiltrating into the glomerulus and interstitium in lupus nephritis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8941444" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10215343" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/916891" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Membranous lupus nephropathy: a clinicopathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6358633" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Pathologic differentiation between lupus and nonlupus membranous glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6606818" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Late onset systemic lupus erythematosus and lupus-like disease in patients with apparent idiopathic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18089685" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Long-term outcome of Chinese patients with membranous lupus nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19279123" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Treatment of membranous lupus nephritis: where are we now?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8785400" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9352738" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Renal vascular lesions in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1094162" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Interstitial immune complex nephritis in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3540691" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Tubulointerstitial disease in lupus nephritis: relationship to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1967662" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Lupus nephritis: correlation of interstitial cells with glomerular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20182417" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/474602" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Immunologically-mediated acute renal failure of nonglomerular origin in the course of systemic lupus erythematosus [SLE]. Report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8659506" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Predominant tubulointerstitial lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3034179" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Occurrence of renal tubular dysfunction in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/842984" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Impaired renal tubular potassium secretion in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35372968" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Idiopathic Hypokalemia in Lupus Nephritis: A Newly Recognized Entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9219160" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Preservation of intercalated cell H(+)-ATPase in two patients with lupus nephritis and hyperkalemic distal renal tubular acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23302713" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8025223" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Renal vascular complications of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20630130" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : True vasculitis in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19074164" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23320601" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : The spectrum of renal thrombotic microangiopathy in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4041134" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Thrombotic thrombocytopenic purpura syndrome in systemic lupus erythematosus: treatment with plasma infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15548564" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Glomerular podocytopathy in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26983707" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Clinical-Morphological Features and Outcomes of Lupus Podocytopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11863121" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Minimal change disease in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31733721" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Lupus Podocytopathy: An Overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19713441" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Lupus podocytopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21051743" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Updates on the treatment of lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22461531" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
